Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Consultation Procedure under Section 35a para. 3b SGB V: Exagamglogene autotemcel (β-thalassaemia); requirement of routine practice data collection and evaluations

of 1 February 2024

The Federal Joint Committee (G-BA) decided the following at its session on 1 February 2024:

I. The consultation procedure on the requirement of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient Exagamglogene autotemcel for the treatment of

"patients 12 years and older with transfusion-dependent β-thalassaemia, for whom no human leukocyte antigen (HLA)-identical, related haematopoietic stem cell donor is available."

is suspended.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 1 February 2024.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 1 February 2024

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken